Xuanzhu Biopharmaceutical Co (FRA:V59) Beginning Cash Position: €1.04 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:V59 Xuanzhu Biopharmaceutical Co Ltd FRA:V59
11 GF Score
Price €1.31
! 1 Warning Sign
View Full Analysis

What is Xuanzhu Biopharmaceutical Co Beginning Cash Position?

Xuanzhu Biopharmaceutical Co FRA:V59 +3.00% 11 Beginning Cash Position is €1.04 Mil as of Dec. 2025. GuruFocus rates FRA:V59 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Xuanzhu Biopharmaceutical Co's Beginning Cash Position for the quarter that ended in Dec. 2025 was €1.04 Mil.

Xuanzhu Biopharmaceutical Co's quarterly Beginning Cash Position increased from Dec. 2024 (€3.32 Mil) to Jun. 2025 (€16.33 Mil) but then declined from Jun. 2025 (€16.33 Mil) to Dec. 2025 (€1.04 Mil).

Xuanzhu Biopharmaceutical Co's annual Beginning Cash Position declined from Dec. 2023 (€28.78 Mil) to Dec. 2024 (€18.74 Mil) and declined from Dec. 2024 (€18.74 Mil) to Dec. 2025 (€16.40 Mil).

Xuanzhu Biopharmaceutical Co Beginning Cash Position Related Terms

Xuanzhu Biopharmaceutical Co Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Xuanzhu Biopharmaceutical Co's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xuanzhu Biopharmaceutical Co Beginning Cash Position Chart

Xuanzhu Biopharmaceutical Co Annual Data
Trend Dec23 Dec24 Dec25
Beginning Cash Position
28.78 18.74 16.40

Xuanzhu Biopharmaceutical Co Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position 0.00 18.30 3.32 16.33 1.04
FRA:V59
11GF Score
Xuanzhu Biopharmaceutical Co Ltd FRA:V59
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xuanzhu Biopharmaceutical Co Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €1.04 Mil mean?
Xuanzhu Biopharmaceutical Co (FRA:V59) has a Beginning Cash Position of €1.04 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Xuanzhu Biopharmaceutical Co and its competitors.
Is Xuanzhu Biopharmaceutical Co's Beginning Cash Position too high?
Xuanzhu Biopharmaceutical Co's current Beginning Cash Position is €1.04 Mil. Overall, Xuanzhu Biopharmaceutical Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Xuanzhu Biopharmaceutical Co's Beginning Cash Position compare to ZTS?
Xuanzhu Biopharmaceutical Co's Beginning Cash Position of €1.04 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Xuanzhu Biopharmaceutical Co and its competitors. Xuanzhu Biopharmaceutical Co's current Beginning Cash Position is €1.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xuanzhu Biopharmaceutical Co stock overvalued right now?
Xuanzhu Biopharmaceutical Co (FRA:V59) has a current Beginning Cash Position of €1.04 Mil. The current Beginning Cash Position is €1.04 Mil. Xuanzhu Biopharmaceutical Co's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Xuanzhu Biopharmaceutical Co (FRA:V59), the current Beginning Cash Position is €1.04 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Xuanzhu Biopharmaceutical Co Business Description

Other Exchanges 02575:Hong Kong
Address Zhubang 2000 Business Center, 2107, Building 2, Balizhuang Xili, Chaoyang District, Beijing, CHN
Xuanzhu Biopharmaceutical Co Ltd is an innovation-driven biopharmaceutical company in China, leveraging its understanding of China's pharmaceutical industry and insights of its clinical needs to improve patient health and life. It has over ten drug assets under active development covering digestive diseases, oncology, and NASH. Its track record also includes the successful development of four drug candidates that were subsequently transferred and/or out-licensed to pharmaceutical companies. Its pipeline is staggered and complementary in structure, covering both validated targets with druggability as well as new mechanisms of action and drug modalities, established therapeutic areas such as oncology, and high-growth potential therapeutic areas such as NASH.
11GF Score

Get the complete analysis for FRA:V59

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.31
Price